Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 27, 2026
Why Is Space Exploration Technologies (SPCX) Stock Down -4.81% Today?

Why Is Space Exploration Technologies (SPCX) Stock Down -4.81% Today?

Key Takeaways

  • SPCX shares fell approximately 4.81% in Monday's session, sliding to an all-time intraday low near $109.53, well below the stock's $135 IPO price from June.
  • The decline comes despite a largely successful Starship Flight 13 test on Friday evening that deployed 20 Starlink V3 satellites and achieved a controlled upper-stage landing — milestones that failed to reignite investor enthusiasm.
  • Mounting valuation concerns, a massive lock-up expiration on August 6, and the looming August 4 earnings report are overwhelming any positive operational catalysts.
  • The stock has now lost roughly half its value from the post-IPO peak of $225.64 reached on June 16, erasing more than $1 trillion in market capitalization.
  • Analyst sentiment remains broadly bullish, with Raymond James reiterating a Strong Buy and Bernstein maintaining a Buy rating — but the near-term technical and liquidity picture remains under heavy pressure.
  • Traders are watching the $110.85 level — the stock's prior all-time intraday low from July 23 — as a critical floor ahead of next week's earnings.

Opening Summary

Shares of Space Exploration Technologies Corp. (SPCX), better known as SpaceX, tumbled 4.81% on Monday to approximately $109.53, extending a punishing sell-off that has now dragged the stock more than 50% below its post-IPO high. Friday's close of $115.07 — itself a record closing low — provided no floor, as the first full trading session following a successful Starship test flight was met with aggressive selling. The decline underscores a deepening crisis of confidence in a valuation that remains among the most expensive in public markets, even as the company's rockets continue to perform.

Starship Success Fails to Halt the Slide

On Friday evening, after the market closed, SpaceX completed Starship Flight 13 — its first test flight since the company's record-breaking IPO in June. The mission achieved several key objectives: the upper-stage Starship spacecraft deployed 20 next-generation Starlink V3 satellites into orbit, executed a clean engine relight in space, and performed a controlled soft landing in the Indian Ocean. SpaceX described the heat shield as the first to return intact, giving engineers unprecedented post-flight data.

Yet the market shrugged. The Super Heavy booster again failed to reignite all of its landing engines, striking the Gulf of Mexico harder than planned — a reminder that full reusability remains an engineering work-in-progress. More fundamentally, the successful flight was widely anticipated, and the stock's prior pricing had already embedded an optimistic scenario for Starship's development timeline. When good news cannot lift a stock, market participants often conclude that the problem lies not with the news but with the price.

Lock-Up Expiration Looms as a Major Overhang

Perhaps the most significant near-term headwind is structural rather than operational. On August 6, approximately 911.5 million shares held by insiders, early investors, and venture capital firms will become eligible for sale as the initial post-IPO lock-up period expires. Because SPCX currently trades well below the $175.50 threshold that would have triggered a phased release, the entire block could hit the market at once — representing nearly 30% of shares outstanding flooding into the public float virtually overnight.

Veteran investors have flagged this as a potential liquidity event. With the stock already under sustained selling pressure, the prospect of a massive supply increase is keeping buyers on the sidelines and emboldening short sellers, who have built positions amounting to roughly 29% of the tradeable float.

IPO Hangover and the AI Valuation Reset

Monday's decline is also the latest chapter in a broader post-IPO reckoning. SpaceX went public at $135 per share on June 12 with a valuation of approximately $1.77 trillion, pricing in years — if not decades — of aggressive growth across its three business segments: space launch, Starlink connectivity, and artificial intelligence. The stock briefly soared to $225.64 before gravity took hold.

Since then, a confluence of factors has punished the shares. The broader market has cooled sharply on high-multiple AI narratives, hitting names like TSLA and GOOGL alongside SPCX. SpaceX's core financials — $4.7 billion in quarterly revenue growing at roughly 15% annually, with steep net losses — struggle to justify a price-to-sales multiple still above 70x even after the sell-off. Competitors such as RKLB and ASTS have outperformed during this period, suggesting capital is rotating toward smaller, less richly valued names in the commercial space sector. Meanwhile, China's successful reusable rocket water landing has added competitive pressure that the market had not fully discounted.

Market Context and Trading Activity

Monday's selling pushed SPCX through its prior intraday low of $110.85 set on July 23, confirming a technical breakdown to a new post-IPO trough. The stock has now declined in six of the last seven trading sessions, with volume consistently running above levels seen in the stock's first weeks of trading — an indication of institutional repositioning rather than retail-driven noise. The Nasdaq-100 inclusion that briefly supported the shares in early July has provided no lasting bid, and sector ETFs with exposure to SpaceX have similarly underperformed the broader industrials complex.

What Comes Next for SPCX

The next two weeks represent a pivotal window for SPCX. On August 4, the company is scheduled to deliver its first quarterly earnings report as a public company — a make-or-break event that will give investors their first official look at post-IPO financials, updated guidance, and management's outlook on Starlink subscriber growth, Starship's path to commercial operations, and the AI division's revenue trajectory. Two days later, the lock-up expiration will test whether fundamental buyers step in to absorb insider supply or whether the stock faces another leg lower.

Wall Street remains divided. Morgan Stanley has characterized current levels as an attractive entry point where the market is ascribing near-zero value to SpaceX's AI business. Raymond James and Bernstein reaffirmed Buy ratings on Monday. Yet Piper Sandler launched coverage with a Hold rating, and HSBC has urged caution. With average analyst price targets still hovering around $235 — more than double current levels — the disconnect between sell-side optimism and market price action has rarely been wider. Traders should expect extreme volatility as these catalysts collide.

Trending AI Robots

In volatile market environments like the one surrounding SPCX, traders increasingly turn to systematic, data-driven strategies to navigate uncertainty. Tickeron's Trending AI Robots page curates a selection of the platform's strongest-performing AI trading bots across thousands of tickers, highlighting only those that are excelling under current market conditions. Bots vary by strategy, timeframe, and performance metrics — from swing trading to trend following — offering traders a diverse toolkit in real time. Explore the Trending AI Robots to see which strategies are leading the market right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: SPCX

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 41.99B. The market cap for tickers in the group ranges from 4.49 to 1.76T. SPCX holds the highest valuation in this group at 1.76T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 3%. For the same Industry, the average monthly price growth was 7%, and the average quarterly price growth was 6%. VOYG experienced the highest price growth at 28%, while EVTL experienced the biggest fall at -36%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 12%. For the same stocks of the Industry, the average monthly volume growth was 83% and the average quarterly volume growth was 43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 67
Price Growth Rating: 52
SMR Rating: 78
Profit Risk Rating: 71
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Profile
Details
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.